In Flat Gene-Expression Market, Affymetrix Will Target Clinical Market and Frugal Labs | GenomeWeb
Affymetrix CEO Stephen Fodor last week said the company plans to revitalize its gene-expression sales by courting more clinical users and introducing more affordable chips for researchers with tight budgets.
Speaking during the company’s fourth-quarter earnings conference call, Fodor said that the expression market in 2006 “was relatively flat. On the other hand, it is, again, a more maturing market in that our strategy in expression is to really push things towards clinical studies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.